Skip to main navigation Logo - Color Analyst Coverage Firm Equity Research Alliance Global Partners Matt Cross BTIG, LLC Robert Hazlett Cantor Fitzgerald Alethia Young H.C. Wainwright Swayampaukula Ramakanth, Ph.D. Verastem Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Verastem Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Verastem Inc. or its management. Verastem Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. E-mail Alerts You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit. Required fields denoted by an asterisk (). Alert Type Verastem Inc End-of-Day Stock Quote Alert Verastem Inc SEC Alert Verastem Inc Calendar Alert Verastem Inc News Alert Email Investor Contact Ajay Munshi Investor Relations 781.469.1579 info@verastem.com Sherri Spear Argot Partners 617.533.0020 sherri@argotpartners.com Investor Kit Corporate Presentation Corporate Latest 10-K Corporate Proxy Statements Corporate Compliance & Business Practices Terms of Use Copyright Statement Privacy Policy Contact © 2021 Verastem, Inc. All Rights Reserved.

LOGO - COLOR Our Science Read Transcript Exploring the Unexplored to Give Patients Better Options No patient with cancer should ever run out of options. At Verastem Oncology, we’re working every day to make sure they don’t. By embracing the power of external partnerships and collaboration, we’re putting our collective knowledge and expertise to work to deliver novel treatment approaches that address areas of high unmet need in RAS pathway-driven cancers. Patients desperately need better treatment options. We’re fighting to give them more possibilities—and more hope. Watch the video to see how customized combinations of VS-6766, a unique dual RAF/MEK inhibitor, including a combination with defactinib, a selective FAK inhibitor, have the potential to greatly expand the number of effective treatments options for these patients. Our Pipeline Verastem Oncology is relentlessly pursuing RAS-targeted treatment combinations with VS-6766. EXPLORE Resources Access Verastem Oncology’s latest posters, presentations, and publications. ACCESS RESOURCES Our Science Learn about VS-6766, an investigational backbone of therapy in RAS pathway-driven cancers. GET THE DETAILS Blocking the RAS Signaling Pathway We are working to realize the full therapeutic potential of targeting the RAS pathway. FIND OUT MORE Terms of Use Copyright Statement Privacy Policy Contact © 2021 Verastem, Inc. All Rights Reserved.